Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 9648.121 | 1.0045 | 1.0138 | 0.6537 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.147 | uM | 9648.121 | 0.6296 | -0.0145 | 0.6537 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.736 | uM | 9648.121 | 0.1757 | -0.8601 | 0.6537 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 3.68 | uM | 9648.121 | 0.4412 | -0.4279 | 0.6537 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 18.4 | uM | 9648.121 | 0.3668 | -0.5688 | 0.6537 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 92 | uM | 9648.121 | 0.0043 | -0.9995 | 0.6537 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 10095.034 | 1.0689 | 1.1766 | 0.7874 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 10095.034 | 0.9666 | 0.9155 | 0.7874 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 10095.034 | 1.0549 | 1.1405 | 0.7874 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 10095.034 | 0.9671 | 0.9168 | 0.7874 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.138 | uM | 10095.034 | 0.7038 | 0.2803 | 0.7874 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.69 | uM | 10095.034 | 0.3432 | -0.4858 | 0.7874 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 3.45 | uM | 10095.034 | 0.3325 | -0.5060 | 0.7874 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 17.2 | uM | 10095.034 | 0.3782 | -0.4183 | 0.7874 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 86.2 | uM | 10095.034 | 0.0078 | -0.9958 | 0.7874 | |
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 7897.007 | 1.0156 | 1.0356 | 0.8772 | |
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 7897.007 | 1.0053 | 1.0121 | 0.8772 | |
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 7897.007 | 0.9388 | 0.8610 | 0.8772 | |
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7897.007 | 0.9199 | 0.8185 | 0.8772 | |
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.138 | uM | 7897.007 | 0.9956 | 0.9899 | 0.8772 | |
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.69 | uM | 7897.007 | 0.3532 | -0.3894 | 0.8772 | |
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7897.007 | 0.3535 | -0.3889 | 0.8772 | |
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 17.2 | uM | 7897.007 | 0.1970 | -0.6861 | 0.8772 | |
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 86.2 | uM | 7897.007 | 0.0004 | -0.9997 | 0.8772 | |
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 9664.121 | 1.0081 | 1.0222 | 0.7294 |